NBP

0.83005.66%
SW

Sean Wuxiong Cao

Chief Business Development Officer & Director

Dr. Sean Wuxiong Cao, Ph.D., MBA, is Director of NovaBridge Biosciences May 28, 2025 and serves as Chief Business Development Officer since September 2025. He is Co-Founder and serves as Director of ENSEM Therapeutics Inc. He served as Chief Executive Officer of ENSEM Therapeutics Inc. He has been Managing Director at C-Bridge Capital Investment Management, Ltd. (formerly known as CBC Group) (formerly known as C-Bridge Capital Partners LLC) since October 2016. Mr. Cao served as Vice President of Global Business Development at Simcere Pharmaceutical Group. Prior to that, he served as Senior Director at Sanofi leading the externalization effort in global research and development. He served as Board of Directors at Simcere of America. He serves as Executive Chairman of NiKang Therapeutics, Inc. Before Sanofi, he was an Associate at New Leaf Venture Partners, a healthcare VC firm based in New York. He worked in the pharmaceutical and diagnostic industries over eight years at Aventis and Johnson & Johnson, before joining New Leaf. He holds a PhD in Microbiology from the University of Virginia, an MBA with honor from the Wharton School of the University of Pennsylvania and a BS in Microbiology from Nankai University, China.

Positions